Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers
Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, today announced the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005724/en/
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers (Photo: Business Wire)
The new entity named “Crown Bioscience & MBL”, is a long-term strategic partnership that is expected to accelerate growth for both companies. The initial focus is to provide preclinical and translational services to expand Crown Bioscience’s offerings in Japan. The agreement will enhance Crown Bioscience’s current distributor model and establish a local presence to ensure premium service delivery in Japan.
Based in Tokyo, Crown Bioscience & MBL will establish a local team led by an experienced General Manager, Hiroki Itou, Executive Officer of MBL and General Manager, Diagnostic & Research Reagents Department at JSR.
The new company will leverage each organisations’ respective areas of excellence and expertise, combining Crown Bioscience’s world-class preclinical and translational service capabilities with MBL’s deep knowledge and experience of the Japanese pharmaceutical market. The company, established in April 2022, is expected to initiate services from September 2022.
Commenting on the establishment of the new company, Armin Spura PhD, CEO of Crown Bioscience, noted that the agreement will extend and deepen the current partnership with MBL. He said: “Japan will play a significant part in Crown Bioscience and MBL’s long-term strategic vision. Our new company has been created to better serve the evolving needs of the Japanese biopharmaceutical community, and to serve our Japanese customers more effectively. I am excited to further develop our synergies with MBL – a trusted partner in the Japanese life sciences sector.”
Hiroki Itou, President of Crown Bioscience & MBL commented: “Our two companies share a deep respect and identical values in the way we conduct business. I am confident that together we will be able to provide a unique and innovative portfolio of services that will accelerate drug discovery and development in Japan.”
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities in the US, Europe and Asia. Find out more: www.crownbio.com.
About Medical & Biological Laboratories Co., Ltd.
Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases, etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, we are contributing to personalized medicine by developing companion diagnostics that predict the effects of drugs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005724/en/
Medical & Biological Laboratories
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westlake Epoxy Confirms ISCC+ Certification at Its Pernis, Netherlands Site23.3.2023 23:19:00 CET | Press release
Westlake Corporation (NYSE: WLK) today announced that Westlake Epoxy’s Pernis, Netherlands site has completed the first sale of certified mass balanced Bisphenol A (BPA). Additionally, the site received mass balance certification for its tracing and handling of sustainable materials in the production of epoxy products for its International Sustainability & Carbon Plus (ISCC+) certification. This is a significant step in Westlake Epoxy’s strategy to integrate renewable carbon materials into its raw material supply chain while reducing energy use and greenhouse gas emissions. All hydrocarbon feedstocks for the liquid epoxy resins produced at the Pernis location have been certified by mass balance to be replaceable by bio-based alternatives. These include the phenol and acetone used to manufacture BPA, as well as the propylene used to manufacture epichlorohydrin (ECH). ISCC+ provides an international, practical, transparent system for the certification of bio-based, bio-circular and circu
The Empire State Building to Light Up in Celebration of the 50 th Anniversary of Pink Floyd’s ‘The Dark Side of the Moon’23.3.2023 23:09:00 CET | Press release
On Friday, March 24, the Empire State Building (ESB) will celebrate the 50th anniversary of Pink Floyd’s legendary album “The Dark Side of the Moon” with a special anniversary version of the famous original album artwork to spin in its mast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005742/en/ The Empire State Building to Light Up in Celebration of the 50th Anniversary of Pink Floyd’s ‘The Dark Side of the Moon’ (Photo: Business Wire) “‘The Dark Side of the Moon’ is as authentic, global, and iconic an album as the Empire State Building is a building, so it is only logical to celebrate it atop ESB’s world-famous tower,” said Anthony E. Malkin, chairman, president, and CEO at Empire State Realty Trust. “On March 24 she will celebrate this milestone anniversary alongside the multitude of Pink Floyd fans throughout the world.” Released in 1973, “The Dark Side of the Moon” is one of the best-selling albums of all time
Palantir Awarded Australian Transaction Reports and Analysis Centre (AUSTRAC) Renewal to Support Financial Criminal Investigations23.3.2023 21:18:00 CET | Press release
Palantir Technologies Inc. (NYSE: PLTR) today announced that the Australian Transaction Reports and Analysis Centre (AUSTRAC) renewed its partnership for the ongoing delivery of an intelligence data analysis platform to support the AUSTRAC mission of protecting Australia’s financial system from criminal abuse. Since 2017, Palantir has partnered with AUSTRAC to optimise their use of financial data in support of criminal investigations. AUSTRAC builds resilience in the financial system and uses financial intelligence and regulation to disrupt money laundering, terrorism financing, and other serious crime. AUSTRAC utilizes Palantir Technologies’ Gotham and Foundry software platforms to integrate and fuse large scale data across their enterprise, driving decisions and operational outcomes. “We are proud to continue and expand our partnership with AUSTRAC and remain firmly committed to supporting their mission,” said Mike Kelly, Head of Palantir Australia. “AUSTRAC personnel are using Palan
Interactive Brokers Expected to Raise Interest Rates to USD 4.33% on Instantly Available Cash23.3.2023 18:59:00 CET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that clients are expected to earn up to USD 4.33% on instantly available cash balances over USD 10,000. Unlike brokerages that offer significantly lower rates, Interactive Brokers conveniently pays interest directly to client brokerage accounts. This eliminates the need for separate sweeps accounts, funds or programs and enables cash to be instantly available. While interest rates available at other brokerages are only USD 0.01% – 2.32%, the market interest paid by Interactive Brokers, is calculated using the Fed Funds rate as the reference rate for USD minus 0.5%. As a result, if interest rates continue to rise as expected, clients of Interactive Brokers will have the opportunity to earn more. “In the current rising rate environment, many investors are considering how to earn more in their brokerage and savings accounts,” said Thomas Peterffy, Founder and Chairman of Interactive Brokers. “Invest
DENZA Partners with DEVIALET on Car Audio System23.3.2023 18:00:00 CET | Press release
On 22nd March 2023, the DENZA x DEVIALET Cooperation Kick-off Evening was held at the Bay Opera of Shenzhen. DENZA and DEVIALET jointly unveiled the DENZA N7, the world's first mass-produced model coming with the DEVIALET car audio system. This cooperation witnesses DENZA become the first brand to apply DEVIALET’s audio system and serves as a paradigm of international cooperation in the global automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005522/en/ DENZA x DEVIALET Cooperation Kick-off Evening (Photo: Business Wire) Zhao Changjiang, General Manager of DENZA, said: “High-quality music brings users enjoyment of life, and intelligent music cockpit is the standard element for the new luxury.” Franck Lebouchard, CEO of DEVIALET, commented, “This is a collaboration between two market leaders with a mission to redefine sound experiences in mobility. Our partnership with DENZA marks a partnership conclud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom